Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia

Acta Neuropsychiatrica

Volumn 28, Issue 3, 2016, Pages 149-156

  Vetlugina, Tamara Parfenovna ^a   Lobacheva, Olga Anatolyevna ^a   Sergeeva, Svetlana Alexandrovna ^b   Nikitina, Valentina Borisovna ^a   Nevidimova, Tatiana Ivanovna ^a   Semke, Arkady Valentinovich ^a  

^a MENTAL HEALTH RESEARCH INSTITUTE   (Russian Federation)

^b Open Joint Stock Company 'Russian Scientific Center for the Safety of Biologically Active Compounds'   (Russian Federation)

Author keywords

interferon ; psychoneuroimmunology; schizophrenia; ultra high dilutions of antibodies to human interferon

Indexed keywords

ANAFERON; GAMMA INTERFERON; HALOPERIDOL; IMMUNOMODULATING AGENT; OLANZAPINE; PHYTOHEMAGGLUTININ; PLACEBO; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ANTIBODY; IFNG PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SCHIZOPHRENIA; TREATMENT DURATION; BLOOD; DOSE RESPONSE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84947104602     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2015.60     Document Type: Article

References (29)

1. LADER M. Neuroleptic-induced deficit syndrome: old problem, new challenge. J Psychopharmacol 1993;7:392-393.
2. STALLER J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 2006; 16:317-326.
3. MULLER N, RIEDEL M, GRUBER R, ACKENHEIL M, SCHWARZ MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci 2000;917:456-467.
4. STROUS RD, SHOENFELD Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006;27:71-80.
5. MULLER N, SCHWARZ MJ. Immunology in schizophrenic disorders. Nervenarzt 2007;78:253-256. 258-260, 262-263.
6. VETLUGINA TP, LOBACHEVA OA, AL'PERINA EL et al. Clinical and experimental research of immunomodulatory effect of amisulpride. Vestn Ross Akad Med Nauk 2012;12:13-17. (in Russian).
7. MULLER N, WAGNER JK, KRAUSE D et al. Impaired monocyte activation in schizophrenia. Psychiatry Res 2012;198: 341-346.
8. NA KS, KIM YK. Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiol 2007;56:55-63.
9. WATANABE Y, SOMEYA T, NAWA H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010;64:217-230.
10. GOEB JL, CAILLEAU A, LAINÉ P et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol 2003;26:5-7.
11. KALYONCU OA, TAN D, MIRSAL H, PEKTAS O, BEYAZYUREK M. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005;19:102-105.
12. MYINT AM, SCHWARZ MJ, STEINBUSCH HW, LEONARD BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009;24:55-68.
13. BELL IR, KOITHAN M. A model for homeopathic remedy effects: low dose nanoparticles, allostatic cross-adaptation, and time-dependent sensitization in a complex adaptive system. BMC Complement Altern Med 2012;12:191.
14. BOKHAN NA, ABOLONIN AF, KRYLOV EN, VETLUGINA TP, IVANOVA SA, EPSTEIN OI. Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission. Bull Exp Biol Med 2003;135(Suppl. 7):171-175.
15. EPSTEIN OI, SHTARK MB, DYGAY AM et al. Pharmacology of ultralow doses of antibodies to endogenous function regulators. Moscow, ID: Publishing House of RAMSci, 2005; (in Russian).
16. EPSTEIN OI. Ultralow doses (the story of one study). Moscow, ID: Publishing House of RAMSci, 2008; (in Russian).
17. KONDRAT'EVA EI, MATVEEVA LA, SHEMYAKINA TA, LOGVINENKO YUI, GOLIKOVA EV, KUTUZOVA EB. The use of anaferon (paediatric formulation) for prophylaxis of acute respiratory viral infections in preschool children. Bull Exp Biol Med 2009;148:266-269.
18. TARASOV SA, KACHANOVA MV, ZHAVBERT ES, DUGINA YL, EPSTEIN OI, SERGEEVA SA. Application of ultralow doses of antibodies to interferon-gamma in complex therapy of bacterial infections and prophylaxis of bacterial complications. Bull Exp Biol Med 2009;148:295-296.
19. TARASOV SA, ZARUBAEV VV, GORBUNOV EA, SERGEEVA SA, EPSTEIN OI. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res 2012;93:219-224.
20. VETLUGINA TP, LOBACHEVA OA, SEMKE AV, SERGEEVA SA, EHPSHTEJN OI, MAL'TSEVA JL. Method of treating patients with schizophrenia. Ru Patent 2415666 C1 2011. Oficial'nyj bjulleten' "Federal'nogo instituta promyshlennoj sobstvennosti" "Izobretenija. Poleznye modeli" [Official Bulletin of the Federal Institute of Industrial Property "Inventions. Useful Models"]. 2011; No. 10. http://www1.fips.ru/Archive/PAT/2011FULL/2011.04.10/DOC/RUNWC1/ 000/000/002/415/666/document.pdf (In Russian).
21. KRASNOV VN, GUROVICH IYA, MOSOLOV SN, SHMUKLER AB. eds Standards for medical assistance to subjects with schizophrenia. Moscow, ID: Publishing House of Psychiatry Research Institute of Roszdrav, 2006; (in Russian).
22. YK KIM, MYINT AM, LEE BH et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1129-1134.
23. STEINER J, JACOBS R, PANTELI B et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci 2010;260: 509-518.
24. REALE M, PATRUNO A, DE LUTIIS MA et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011;25:13 doi: 10.1186/ 1471-2202-12-13.
25. EPSTEIN OI. The phenomenon of release activity and the hypothesis of 'spatial' homeostasis. Usp Fiziol Nauk 2013;44:54-76.
26. ZHU J, YAMANE H, PAUL WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010;28:445-489.
27. MARGOLESE HC, CHOUINARD G, KOLIVAKIS TT, BEAUCLAIR L, MILLER R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50: 541-547.
28. YOSHIDA K, BIES RR, SUZUKI T et al. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophr Res 2014;153:184-188.
29. HM AN, YL TAN, SHI J et al. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr Res 2015;162:261-268.